Cargando…

Comments on "Why not use it all?".

Detalles Bibliográficos
Autores principales:	Goodman, J I, Acosta, D
Formato:	Texto
Lenguaje:	English
Publicado:	1999
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1566714/ https://www.ncbi.nlm.nih.gov/pubmed/10627175

Ejemplares similares

"Why not use it all?" Another view.
por: Landrigan, P J
Publicado: (1999)

Comment: Why are females with Fabry disease affected?
por: Beck, Michael, et al.
Publicado: (2019)

In Response to Comment On: Why Racial Justice Matters in Radiation Oncology
por: Gibbs, Iris C., et al.
Publicado: (2020)

Comment on “Mental health: why it still matters in the midst of a pandemic”
por: Gonzalez-Diaz, Jairo M., et al.
Publicado: (2020)

Why not use it all?
por: Lucier, G W
Publicado: (1999)

Why “covering all” in the DOTS program is not necessarily “all being covered” by the DOTS program
por: Pinto, Lancelot Mark, et al.
Publicado: (2010)

Comment on “Surgically Resected Gall Bladder: Is Histopathology Needed for All?”
por: Barreto, Savio George
Publicado: (2016)

Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
por: Mascitelli, Luca, et al.
Publicado: (2017)

Comment on ‘Statin use and all-cancer survival: prospective results from the Women's Health Initiative'
por: Ravnskov, Uffe
Publicado: (2017)

Reply to Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
por: Wang, Ange, et al.
Publicado: (2017)

Response to comments on: All India Ophthalmological Society (AIOS) task force guidelines to prevent intraocular infections
por: Verma, Lalit, et al.
Publicado: (2022)

Tightening Up the Nomenclature for Non-Physician Clinicians: Why Not Call All of Them Physician Assistants?
por: Kuilman, Luppo, et al.
Publicado: (2015)

Why sequence all eukaryotes?
por: Blaxter, Mark, et al.
Publicado: (2022)

Comment on ‘Updated investigations of cancer excesses in individuals born or resident in the vicinity of Sellafield and Dounreay': premature all-clear for nuclear power
por: Fairlie, I, et al.
Publicado: (2015)

Extensive enactivism: why keep it all in?
por: Hutto, Daniel D., et al.
Publicado: (2014)

Choosing the Correct Double-Lumen Tube: Why One Size Cannot Fit All Just Yet
por: Gangakhedkar, Gauri R.
Publicado: (2022)

Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
por: Krebs-Brown, Axel, et al.
Publicado: (2019)

Why Don’t All Individuals Who Undergo Dura Mater/Arachnoid Puncture Develop Postdural Puncture Headache?
por: Valenca, Marcelo M., et al.
Publicado: (2012)

Response to comments on: Comparison of three newer generation freely available intraocular lens power calculation formulae across all axial lengths
por: Khatib, Zain I, et al.
Publicado: (2021)

Response to Condon et al. comments on “Cancer clusters in the USA: What do the last twenty years of state and federal investigations tell us?”
por: Goodman, Michael, et al.
Publicado: (2013)

Comments on "exposing ourselves to art".
por: Weiss, A L, et al.
Publicado: (1997)

Comments on "Trouble in paradise".
por: Tummons, P
Publicado: (1998)

Comment from the Annals
por: Alzahrani, Ali. S.
Publicado: (2008)

Comment on Nuño Solinís R, et al. “Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence”
por: Cacoub, Patrice
Publicado: (2017)

Comments on the Risk of Gout in Patients with Psoriasis [Letter]
por: Yeh, Wen-Bin, et al.
Publicado: (2022)

Comments on "Estrogenicity of resin-based composites and sealants used in dentistry".
por: Imai, Y
Publicado: (1999)

Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
por: Concordet, D., et al.
Publicado: (2019)

Comment on: use of blood biomarkers to screen for obstructive sleep apnea
por: Abrams, Burton
Publicado: (2018)

Why Are We by All Creatures Waited on?
por: Potter, Polyxeni
Publicado: (2012)

We are all aging, and here's why
por: Shinde, Atharva, et al.
Publicado: (2022)

WHY ASTHMA STILL KILLS
por: O’ Kane, Rebecca
Publicado: (2017)

Why PAPR suits us
por: Mostafa, H.
Publicado: (2020)

Comments on "What is a tumor promoter?".
por: Trosko, J E
Publicado: (1999)

Comments on Lucire and Crotty, 2011
por: Loonen, Anton JM, et al.
Publicado: (2016)

Response to comment by G. Borasi
por: Brüningk, Sarah Catharina, et al.
Publicado: (2017)

Comment on Havens and colleagues (2019)
por: Hinz, Hariet L, et al.
Publicado: (2019)

Response to the comment by Dr Yarlas
por: Aimo, Alberto
Publicado: (2021)

Comments on: All India Ophthalmic Society-Indian Journal of Ophthalmology Consensus statement on preferred practices during COVID-19 Pandemic
por: Sampangi, Raju, et al.
Publicado: (2020)

Comments on: Comparison of three newer generation freely available intraocular lens power calculation formulae across all axial lengths
por: Shrivastava, Ankur K, et al.
Publicado: (2021)

Comment on the intravenous tranexamic acid use in revision total joint arthroplasty
por: He, Jieyu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_325ee8798iuf02n4lero5t29ir